Layered Unitary Dosage Forms Patents (Class 424/472)
-
Publication number: 20120045509Abstract: The present invention refers to pharmaceutical composition comprising a DPP-IV inhibitor.Type: ApplicationFiled: October 27, 2011Publication date: February 23, 2012Inventors: Bernd Michael Loeffler, Alexander MacDonald, Cynthia Rocha, Eric Worth
-
Patent number: 8114435Abstract: An oral pharmaceutical dosage form comprising an acid susceptible proton pump inhibitor and one or more NSAIDs in a fixed formulation, wherein the proton pump inhibitor is protected by an enteric coating layer. The fixed formulation is in the form of an enteric coating layered tablet, a capsule or a multiple unit tableted dosage form. The multiple unit dosage forms are most preferred. The new fixed formulation is especially useful in the treatment of gastrointestinal side-effects associated with NSAID treatment.Type: GrantFiled: February 9, 2009Date of Patent: February 14, 2012Assignee: AstraZeneca ABInventors: Helene Depui, Per Lundberg
-
Publication number: 20120034303Abstract: A pharmaceutical formulation comprising an erosion matrix comprising one or more fumaric acid esters as well as one or more rate-controlling agents, wherein erosion of said erosion matrix permits controlled release of said fumaric acid ester(s).Type: ApplicationFiled: January 8, 2010Publication date: February 9, 2012Applicant: FORWARD PHARMA A/SInventors: Henrik Nilsson, Roland Rupp
-
Publication number: 20120021052Abstract: Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.Type: ApplicationFiled: September 7, 2011Publication date: January 26, 2012Applicant: COSMO TECHNOLOGIES LIMITEDInventors: ROBERTO VILLA, Massimo Pedrani, Mauro Ajani, Lorenzo Fossati
-
Publication number: 20120015031Abstract: A gastro-retentive pharmaceutical dosage form comprising a therapeutically effective amount of at least one opioid, at least one form of acetaminophen, optionally an opioid antagonist and at least one pharmaceutically acceptable excipient, which dosage form is retained in the stomach for at least four hours and is suitable for once daily or twice daily administration. Also provided is a method of treating pain by administering the dosage form to a patient in need thereof. The acetaminophen is either in slow release form or in immediate release form or as combination of both.Type: ApplicationFiled: July 13, 2011Publication date: January 19, 2012Applicant: Grunenthal GmbHInventor: Ramesh SESHA
-
Publication number: 20120009259Abstract: The present invention is directed a pharmaceutical compositions for co-therapy treatment and prevention of glucose-related disorders such as Type 2 diabetes mellitus and Syndrome X.Type: ApplicationFiled: July 6, 2011Publication date: January 12, 2012Inventors: Urbain Alfons Clementina Delaet, Anne Faure, Philip Erna Hortentia Gilbert Heyns, Eugeen Maria Jozef Jans, Aniruddha Railkar
-
Patent number: 8092831Abstract: The present invention relates to an oral pharmaceutical formulation that employs: (1) a compressed core containing a decongestant or pharmaceutically acceptable salt thereof; (2) a delayed release coating on the compressed core and (3) immediate release therapeutic amounts of a decongestant and an antihistamine.Type: GrantFiled: November 8, 2002Date of Patent: January 10, 2012Assignee: Andrx Pharmaceuticals, LLCInventors: Unchalee Kositprapa, Mongkol Sriwongjanya
-
Publication number: 20120003312Abstract: Multilayer minitablets for oral administration of a combination of active pharmaceutical ingredients which release the active pharmaceutical ingredient at different release rates are described.Type: ApplicationFiled: June 22, 2011Publication date: January 5, 2012Applicant: Aptapharma, Inc.Inventors: Siva Rama Krishna Nutalapati, Rakeshkumar Khushalbhai Lad
-
Patent number: 8084058Abstract: A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative and a disintegrating agent is herein disclosed and described. The dosage formulation exhibits a significant increase in bioavailability of the thiazolidinedione derivative component compared to conventional immediate release dosage forms containing only a thiazolidinedione derivative.Type: GrantFiled: March 30, 2005Date of Patent: December 27, 2011Assignees: Watson Pharmaceuticals, Inc., Takeda Pharmaceutical, Co. Ltd.Inventors: Unchalee Lodin, Jack Cardinal, Avinash Nangia
-
Patent number: 8084059Abstract: The invention pertains to a dosage form 10 and to administering an antidepressant medicament 16 for an extended period of time in a rate-known dose.Type: GrantFiled: September 15, 2006Date of Patent: December 27, 2011Assignee: ALZA CorporationInventors: David Emil Edgren, Gurdish Kaur Bhatti, Zahedeh Hatamkhani, Patrick S. L. Wong
-
Publication number: 20110311627Abstract: Pharmaceutical compositions in the form of tablets are disclosed including water-soluble active ingredients such as levetiracetam and a polymer component which primarily includes water-insoluble polymers comprising between 60% and 100% of the polymer component in the tablet core, preferably the entire polymer component in the tablet core. The pharmaceutical compositions can also include an extended-release coating including both water-soluble and water-insoluble polymers.Type: ApplicationFiled: June 16, 2010Publication date: December 22, 2011Inventors: Mummini Aruna Murty, Boyong Li
-
Publication number: 20110305756Abstract: A coated solid preparation includes an active ingredient including valproic acid or a pharmacologically acceptable salt thereof, and a coating layer containing polyvinyl alcohol and swelling clay coating the active ingredient wherein mass ratio of the polyvinyl alcohol to the swelling clay is 8:2 to 3:7 and the swelling clay is dispersed as a laminated structure.Type: ApplicationFiled: March 3, 2010Publication date: December 15, 2011Applicant: TORAY INDUSTRIES, INC.Inventors: Yuki Hayashi, Ryoji Yoshii, Yasuhide Horiuchi
-
Publication number: 20110300208Abstract: A pharmaceutical tablet adapted for accurate division of a dose of a drug into two or more smaller doses, which tablet has two or more segments.Type: ApplicationFiled: August 15, 2011Publication date: December 8, 2011Inventors: Lawrence Solomon, Allan S. Kaplan
-
Patent number: 8071130Abstract: The present invention intends to provide a solid preparation which contains an insulin sensitizer and an active ingredient other than an insulin sensitizer, and exhibits dissolution behavior of an insulin sensitizer similar to that of an insulin sensitizer from “a solid preparation containing only an insulin sensitizer as an active ingredient”. The solid preparation comprises “a part containing coated particles in which the particles containing an insulin sensitizer are coated with lactose or a sugar alcohol” and “a part containing an active ingredient other than an insulin sensitizer”.Type: GrantFiled: December 21, 2006Date of Patent: December 6, 2011Assignee: Takeda Pharmaceutical Company LimitedInventors: Kenichiro Kiyoshima, Kenji Nakamura, Tetsuya Kawano, Masafumi Misaki
-
Patent number: 8067029Abstract: The present invention relates to an improved gelatinous coated dosage form having two end regions coated with gelatinous materials and an exposed circumferential band. Openings are provided in at least the exposed band to reveal the core material. The invention also relates to methods for manufacturing such gelatinous coated dosage forms.Type: GrantFiled: July 23, 2004Date of Patent: November 29, 2011Assignee: McNeil-PPC, Inc.Inventors: Roger A. Rinker, Nicholas J. Casale, James H. Comly, Brenda Pollock, Atul Ayer, Johan Geerke, Martin Costello, Dennis Wieand, Kishor Parekh
-
Publication number: 20110287095Abstract: Methods for producing stabilized solid dosage form pharmaceutical compositions are provided. In particular, methods for preparing protected granules containing morphinans, and solid dosage form pharmaceutical compositions produced using the morphinan-protected granules are provided.Type: ApplicationFiled: June 22, 2011Publication date: November 24, 2011Applicant: Mallinkckrodt Inc.Inventors: Jae Han Park, Tiffani Eisenhauer, Anish Dhanarajan, Vishal K. Gupta, Stephen Overholt
-
Publication number: 20110274751Abstract: A multilayered solid oral pharmaceutical formulation of trimetazidine or a pharmaceutically acceptable salt or polymorph of trimetazidine wherein one layer of said formulation provides controlled release, while the other layer provides immediate release.Type: ApplicationFiled: May 3, 2011Publication date: November 10, 2011Applicant: Sanovel Ilac Sanayi Ve Ticaret Anonim SirketiInventors: Umit Cifter, Ali Turkyilmaz, Nur Pehlivan Akalin, Aylin Yildirim, Levent Oner
-
Publication number: 20110268799Abstract: A dosage form that provides a controlled release solid dosage form for the oral administration of a central nervous system stimulant, preferably methylphenidate hydrochloride.Type: ApplicationFiled: July 11, 2011Publication date: November 3, 2011Applicant: ANDRX PHARMACEUTICALS, INC.Inventors: Manesh Dixit, Chih-Ming Chen, Xiu-Xiu Cheng, Jianbo Xie
-
Publication number: 20110262539Abstract: Methods and compositions are provided which comprise effective amounts of analgesic to treat a subject, including reducing or eliminating an adverse effect associated with the analgesic.Type: ApplicationFiled: December 14, 2010Publication date: October 27, 2011Applicant: Charleston Laboratories, Inc.Inventors: Paul BOSSE, John Ameling, Bernard Schachtel, Ray Takigiku
-
Patent number: 8043630Abstract: Drugs are formulated as oral dosage forms for controlled release in which the release rate limiting portion is a shell surrounding the drug-containing core. The shell releases drug from the core by permitting diffusion of the drug from the core. The shell also motes gastric retention of the dosage form by swelling upon imbibition of gastric fluid to size that is retained in the stomach during the postprandial or fed mode.Type: GrantFiled: April 29, 2010Date of Patent: October 25, 2011Assignee: Depomed, Inc.Inventors: Bret Berner, Jenny Louie-Helm, Gloria Gusler, John N. Shell
-
Publication number: 20110229566Abstract: There is provided a single unit oral dose pharmaceutical composition comprising a) levodopa or salts thereof from about 50 mg to about 300 mg in extended release form, b) carbidopa or salts thereof from about 10 mg to about 100 mg in extended release and c) entacapone or salts thereof from about 100 mg to about 1000 mg in immediate release form, optionally with other pharmaceutically acceptable excipients. The invention also relates to process of preparation of such compositions.Type: ApplicationFiled: August 22, 2009Publication date: September 22, 2011Inventors: Yatendra Kumar Gupta, Girish Kumar Jain, Munish Talwar, Manoj Mashalkar
-
Publication number: 20110217371Abstract: Disclosed is a controlled-release microparticle: including a matrix comprising a pharmacologically active component; and a controlled-release layer comprising a substance which forms a controlled-release stratum on the matrix. The disclosed controlled-release microparticle not only allows effective dual release control of a drug but can also exhibit outstanding dissolution characteristics even when a small amount of coating substance is used.Type: ApplicationFiled: November 10, 2009Publication date: September 8, 2011Applicant: AMOREPACIFIC CORPORATIONInventors: Kwang-Hyun Shin, Jaekwan Kim, Jai-ll Jun, Deok-Ki Hong, Joon-Ho Bae
-
Publication number: 20110212175Abstract: Disclosed herein is a combination therapy and a combination preparation of an angiotensin-II-receptor blocker and an HMG-CoA reductase inhibitor characterized in that the angiotensin-II-receptor blocker is absorbed substantially later than the HMG-CoA reductase inhibitor. As the angiotensin-II-receptor blocker and the HMG-CoA reductase inhibitor are released at different times, the present combination therapy prevents competitive inhibition between the two drugs and side effects, as well as simultaneously provides synergistic effects for each active ingredient and convenience of taking the drugs.Type: ApplicationFiled: May 11, 2011Publication date: September 1, 2011Applicant: HANALL BIOPHARMA CO., LTD.Inventors: Sung Wuk Kim, Sung Soo Jun, Young Gwan Jo, Ja Seong Koo, Jae Woon Son
-
Publication number: 20110195116Abstract: This invention relates to a pharmaceutical dosage form for the delivery of at least one active pharmaceutical ingredient (API) or the pharmaceutically active salts and isomers thereof, to a desired absorption location of the human or animal body, preferably the gastrointestinal tract, in a predetermined rate-modulated manner. The dosage form is orally ingestible and is in the form of a multi-layered tablet preferably three layers and each layer includes an API or capsule containing a multiplicity of multi-layered granules. Each layer contains one or more APIs mixed or blended with at least one and preferably a matrix of polymers and, where appropriate, excipients, which, in use, inhibit release of an API in a region of the gastrointestinal tract other than the desired absorption location and, thus, facilitate release of the API in a rate controlled manner when in the desired absorption location. Methods of manufacturing said dosage form are further disclosed.Type: ApplicationFiled: August 18, 2009Publication date: August 11, 2011Applicant: ADCOCK INGRAM HEALTHCARE PTY LIMITEDInventors: Kim Melissa Hobbs, Viness Pillay, Yahya Essop Choonara, Bradley Ryan Parsons
-
Patent number: 7993673Abstract: A dosage form such as a swallow tablet or a capsule formulation is described comprising paracetamol, low levels of sodium bicarbonate or potassium bicarbonate or mixtures thereof, and at least one pharmaceutically acceptable excipient.Type: GrantFiled: June 3, 2002Date of Patent: August 9, 2011Assignee: SmithKline Beecham LimitedInventor: Timothy James Grattan
-
Publication number: 20110189279Abstract: The invention relates to pharmaceutical compositions with modified release properties comprising 5-Chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid and process of preparing such compositions.Type: ApplicationFiled: August 10, 2009Publication date: August 4, 2011Applicant: RATIOPHARM GMBHInventors: Katrin Rimkus, Frank Muskulus, Sandra Brueck, Jana Paetz
-
Patent number: 7988998Abstract: A sustained-release tramadol formulation oral administration is provided which, upon initial administration of one dose, provides an analgesic effect within 2 hours, which analgesic effect continues for at least 24 hours after administration.Type: GrantFiled: April 22, 2005Date of Patent: August 2, 2011Assignees: Labopharm Inc., Labopharm Europe Limited, Labopharm (Barbados) LimitedInventors: Vincent Lenaerts, Patricia Laure Ouadji-Nijki, Jonathan Bacon, Rachid Ouzérourou, Sonia Gervais, Miloud Rahmouni, Damon Smith
-
Patent number: 7988996Abstract: Described is a compressed multiple layer pharmaceutical tablet that has a height that exceeds the width of the tablet. The height is measured vertically from the top to the bottom of the tablet while it is in the tablet die in which it is fully compressed, after compression has been completed. The width is measured as the greatest horizontal dimension of the tablet at a location halfway between the top and the bottom of the tablet, except that when the horizontal cross-section of the tablet is substantially rectangular, the width is defined by locating the two shorter sides of the perimeter of the horizontal cross-section, and measuring the length of a line that is at right angle to the shorter sides. The layers can form a segment or, preferably, more than one segment.Type: GrantFiled: November 21, 2006Date of Patent: August 2, 2011Assignee: Accu-Break Technologies, Inc.Inventors: Lawrence Solomon, Allan S. Kaplan
-
Patent number: 7985427Abstract: The invention relates to a gastric juice-resistant device for releasing active substance excipients having delayed intestinal passage from a gastric juice-resistant enclosure, and which serves to increase the active substance concentration in the intestines. The inventive device is characterized in that the active substance excipient containing at least one active substance is provided in the form of a multiparticulate preparation whose individual particles have mucoadhesive properties. The invention also relates to a method for producing said device.Type: GrantFiled: April 22, 2002Date of Patent: July 26, 2011Assignee: LTS Lohmann Therapie-Systeme AGInventors: Despina Solomonidou, Markus Krumme, Bodo Asmussen, Joerg Kreuter
-
Publication number: 20110177168Abstract: A pharmaceutical composition comprising an immediate release phase and a sustained release phase of paracetamol is described which has a unique in vitro dissolution profile resulting in advantageous pharmacokinetic properties.Type: ApplicationFiled: March 29, 2011Publication date: July 21, 2011Inventors: Shing Yue CHAN, Timothy James GRATTAN, Bounkhiene SENGMANEE
-
Publication number: 20110177167Abstract: An oral dosage form comprising a pharmaceutical tablet of one or more layers, one of which carries a biologically active substance; the formulation of said tablet includes different percentages of hydrophilic and lipophilic polymeric materials, and adjuvant substances. The tablets of the present invention show a release rate which is independent from the amounts of active substance present in the tablet.Type: ApplicationFiled: February 7, 2011Publication date: July 21, 2011Applicant: Jagotec AGInventors: Guy Vergnault, Pascal Grenier, Lauretta Maggi, Ubaldo Conte
-
Publication number: 20110165234Abstract: A controlled release dosage form of venlafaxine that comprises an immediate release pellet and an extended release pellet.Type: ApplicationFiled: March 18, 2011Publication date: July 7, 2011Applicant: ANDRX PHARMACEUTICALS, LLCInventors: Manesh Dixit, Xiu-Xiu Cheng, Avinash Nangia, Chin Ming Chen
-
Publication number: 20110165239Abstract: The present invention provides stable pharmaceutical compositions comprised of atorvastatin and sodium bicarbonate or L-arginine. The compositions are prepared as bulk drug compositions and also as oral dosage units, such as tablets or capsules. The compositions are useful for preparation of monolithic and bi-layer tablets containing atorvastatin as the only active agent or combined with one or more additional active agents. The compositions are useful for treating hypercholesterolemia and related conditions.Type: ApplicationFiled: September 21, 2009Publication date: July 7, 2011Inventors: Laman Alani, Soumojeet Ghosh
-
Patent number: 7972625Abstract: The invention relates to coated tablets comprising the pharmaceutically active substance diclofenac. Said tablets further comprise a single film coating.Type: GrantFiled: September 23, 2004Date of Patent: July 5, 2011Assignee: Novartis AGInventors: Isabelle Rault, Giovanna Marzano
-
Publication number: 20110159094Abstract: A novel composition comprising a tablet, comprising a highly soluble active pharmaceutical ingredient, which is then coated with a coating. The core is preferably a tablet. The coating preferably comprises any type of suitable extended release polymer, with the proviso that the polymer does not comprise an enteric polymer.Type: ApplicationFiled: December 27, 2010Publication date: June 30, 2011Inventors: Liat ONN, Avi AVRAMOFF
-
Publication number: 20110159095Abstract: The disclosure relates to a pharmaceutical formulation, for example a tablet, adapted for delayed and sustained release of hydrocortisone and a treatment regime that uses said tablet in the treatment of adrenal insufficiency.Type: ApplicationFiled: September 17, 2009Publication date: June 30, 2011Inventors: Hiep Huatan, Richard Ross
-
Publication number: 20110159089Abstract: An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (G1) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided.Type: ApplicationFiled: March 4, 2011Publication date: June 30, 2011Applicant: INSPIRION DELIVERY TECHNOLOGIES, LLCInventors: Manish S. SHAH, Ray Difalco
-
Publication number: 20110150990Abstract: An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided.Type: ApplicationFiled: March 4, 2011Publication date: June 23, 2011Applicant: INSPIRION DELIVERY TECHNOLOGIES, LLCInventors: Manish S. SHAH, Ray Difalco
-
Publication number: 20110150991Abstract: An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided.Type: ApplicationFiled: March 4, 2011Publication date: June 23, 2011Applicant: INSPIRION DELIVERY TECHNOLOGIES, LLCInventors: Manish S. SHAH, Ray Difalco
-
Publication number: 20110150971Abstract: An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided.Type: ApplicationFiled: March 4, 2011Publication date: June 23, 2011Applicant: INSPIRION DELIVERY TECHNOLOGIES, LLCInventors: Manish S. SHAH, Ray DIFALCO
-
Publication number: 20110150974Abstract: A medicament used for prophylactic and/or therapeutic treatment of xerostomia, which is in the form for oral mucosal administration comprising a spirooxathiolane quinuclidine derivative represented by the following general formula (I) or an acid addition salt thereof: [Formula 1] (wherein R1 and R2 may be the same or different, and independently represent a hydrogen atom, an alkyl group, a cyclopentyl group, a cyclohexyl group, a monoaryl- or diaryl-substituted methylol group, or an aryl-substituted alkyl group) as an active ingredient.Type: ApplicationFiled: August 4, 2005Publication date: June 23, 2011Applicants: DAIICHI PHARMACEUTICAL CO., LTD., SAITAMA DAIICHI PHARMACEUTICAL CO., LTD.Inventors: Noriko Nakajima, Norihiro Shinkai, Hitoshi Yamauchi, Masahiko Kikuchi
-
Patent number: 7964216Abstract: The present invention provides to a method of administration of two or more therapeutically active agents comprising orally administering to a patient a spaced drug delivery system, wherein the time of release of the two or more therapeutically active agents is designed to provide desired control on the disease condition. The present invention also provides a method of administration of two or more therapeutically active agents comprising orally administering to a patient a spaced drug delivery system at a specified time prior to food intake by the patient. The present invention further provides a spaced drug delivery system that releases two or more antidiabetic agents at different times after oral administration, for the treatment of diabetes mellitus or conditions associated with diabetes mellitus.Type: GrantFiled: January 11, 2002Date of Patent: June 21, 2011Assignee: Sun Pharma Advanced Research Company LimitedInventors: Dilip Shantilal Shanghvi, Kirti Wardhaman Ganorkar, Yashoraj Rupsinh Zala, Nitin Bhalachandra Dharmadhikari, Satish C Khanna
-
Patent number: 7951400Abstract: A coated tablet formulation is provided which includes a medicament such as the DPP4-inhibitor, saxaglipitin or its HCl salt, which is subject to intra-molecular cyclization, which formulation includes a tablet core containing one or more fillers, and other conventional excipients, which tablet core includes a coating thereon which may include two or more layers, at least one layer of which is an inner seal coat layer which is formed of one or more coating polymers, a second layer of which is formed of medicament which is the DPP4-inhibitor and one or more coating polymers, and an optional, but preferable third outer protective layer which is formed of one or more coating polymers. A method for forming the coated tablet is also provided.Type: GrantFiled: May 25, 2005Date of Patent: May 31, 2011Assignee: Bristol-Myers Squibb CompanyInventors: Divyakant S. Desai, Bing V. Li
-
Publication number: 20110123612Abstract: The present invention provides a pharmaceutical formulation comprising an immediate-release compartment containing an angiotensin-2 receptor blocker (ARB) as a pharmacologically active ingredient and an extended-release compartment containing a non-dihydropyridine calcium channel blocker as a pharmacologically active ingredient. Since the disclosed formulation enables the release of the two ingredients at a different time, it reduces side effects and increases the effects of the drug more than the case of separately administering the ingredients each at the same time. In addition, the formulation maximizes the effects of drug at the time of day when the complication risk of cardiovascular system diseases is highest.Type: ApplicationFiled: April 3, 2009Publication date: May 26, 2011Inventors: Sung Wuk Kim, Sung Soo Jun, Ah Ram Lee, Sang Ouk Sun, Jin Won Choi, Young Gwan Jo, Ja Seong Koo
-
Patent number: 7943170Abstract: A pharmaceutical composition comprising an immediate release phase and a sustained release phase of paracetamol is described which has a unique in vitro dissolution profile resulting in advantageous pharmacokinetic properties.Type: GrantFiled: April 12, 2001Date of Patent: May 17, 2011Assignee: SmithKline Beecham LimitedInventors: Shing Yue Chan, Timothy James Grattan, Bounkhiene Sengmanee
-
Publication number: 20110111021Abstract: The present invention provides a pharmaceutical preparation including a compartment containing a renin inhibitor as a pharmacologically active ingredient, and a compartment containing an HMG-CoA reductase inhibitor as a pharmacologically active ingredient, wherein one compartment is a prior-release compartment and the other compartment is a delayed-release compartment. The combination preparation of the present invention can deliver a renin inhibitor and an HMG-CoA reductase inhibitor with a time interval at a specific speed, thus reducing undesirable side-effects, improving the drug efficacy and promoting the patient compliance. Further, the pharmaceutical preparation of the present invention has pharmacological, clinical, scientific and economical advantages in the prevention or treatment of metabolic syndromes, cardiovascular diseases, renal diseases and the like, as compared with the complex drug regimens in which medicament ingredients are taken individually or simultaneously.Type: ApplicationFiled: February 23, 2009Publication date: May 12, 2011Applicant: HANALL BIOPHARMA CO., LTD.Inventors: Sung Wuk Kim, Sung Soo Jun, Young Gwan Jo, Ja Seong Koo, Jaw Woon Son, Jin Wook Kim
-
Publication number: 20110111027Abstract: The present invention provides a solid immediate release dosage form adapted for oral administration of GHB. The solid immediate release dosage form includes an immediate release formulation comprising a relatively high weight-percentage of GHB with a bioavailability similar to that of a liquid GHB dosage form.Type: ApplicationFiled: May 4, 2010Publication date: May 12, 2011Applicant: JAZZ PHARMACEUTICALS, INC.Inventors: ANDREA MARIE ROURKE, MAURA PATRICIA MURPHY, JAMES FREDERICK PFEIFFER, CLARK PATRICK ALLPHIN, ALYA KHAN MCGINLAY
-
Publication number: 20110097400Abstract: A magnesium-based system suitable for use in skincare comprises (a) a first magnesium source in the form of a progressive-release oral tablet exhibiting in vitro, after 2 h in 0.1N HCl medium, a rate of dissolution (?) of the magnesium contained therein of less than or equal to 60% by weight relative to the total weight of the Mg provided by the first magnesium source, and (b) a second magnesium source in a topical preparation. A method for treating skin for stress, fatigue or skin barrier deficiencies, as well as for stratum corneum hydration, includes orally and topically administering magnesium sources (a) and (b), respectively.Type: ApplicationFiled: March 20, 2009Publication date: April 28, 2011Inventor: Fabienne Joanny
-
Patent number: 7931915Abstract: A controlled release dosage form of venlafaxine that comprises an immediate release pellet and an extended release pellet.Type: GrantFiled: November 19, 2008Date of Patent: April 26, 2011Assignee: Andrx Pharmaceuticals, LLCInventors: Manesh Dixit, Xiu-Xiu Cheng, Avinash Nangia, Chih Ming Chen
-
Patent number: 7932258Abstract: The invention relates to the use of a partially neutralized, anionic (meth)acrylate copolymer comprising radically polymerized units of 25 to 95 percent by weight of C1 to C4 alkyl esters of acrylic or methacrylic acid and 5 to 75 percent by weight of (meth)acrylate monomers with an anionic group, at least 4 percent of which are neutralized by means of a base, for producing a medicament that is provided with an active substance-containing core and is coated with the partially neutralized, anionic (meth)acrylate copolymer. The medicament releases at least 30 percent of the active substance contained therein in 30 minutes at a pH at which the active substance is sufficiently soluble and stable and at which the corresponding medicament that is coated with the non-neutralized anionic (meth)acrylate polymer releases less than 10 percent of the active substance contained therein.Type: GrantFiled: April 5, 2006Date of Patent: April 26, 2011Assignee: Evonik Roehm GmbHInventors: Hans-Ulrich Petereit, Manfred Assmus